



IFW

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/789,835	
	Filing Date	02/27/2004	
	First Named Inventor	THOMPSON, Todd A. et al.	
	Art Unit	N/A	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	103	Attorney Docket Number	054030-0052

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement 14 references (96 sheets) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard Letter re IDS Transmittal Form Fee Transmittal
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name			
Signature			
Printed name	Charles L. Leeck		
Date	7-20-04	Reg. No.	50,343

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to/Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Mail Stop Amendment			
Signature			
Typed or printed name	Ruth Ellen Genac	Date	09/30/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

Complete if Known

Application Number	10/789,835
Filing Date	02/27/2004
First Named Inventor	THOMPSON, Todd A. et al.
Examiner Name	Unknown
Art Unit	N/A
Attorney Docket No.	054030-0052

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number
Deposit
Account
Name

07-1509

Godfrey & Kahn, S.C.

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)				(\$)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	-20** =	X	
Independent Claims	-3** =	X	
Multiple Dependent			

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)				(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

(Complete (if applicable))

Name (Print/Type)	Charles L. Leeck	Registration No. (Attorney/Agent)	50,343	Telephone	414-273-3500
Signature		Date	2-30-04		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Applicant: Todd A. Thompson, et al.
Application No.: 10/789,835
For: CHROMAN-DERIVED ANTI-ANDROGENS FOR
TREATMENT OF ANDROGEN-MEDIATED DISORDERS
Filed: February 27, 2004
Group Art Unit: N/A
Examiner: Unknown
Attorney Docket No.: 054030-0052

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	<u>CERTIFICATE OF MAILING UNDER 37 CFR 1.8</u>
	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>09/30/2004</u>
	<u>Ruth Ellen Genac</u> (Typed or printed name of person mailing paper or fee)
	<u>Ruth Ellen Genac</u> (Signature of person mailing paper or fee)

Dear Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, the Applicant submits the references listed below for consideration.

Non-Patent References:

BRIGELIUS-FLOHE, R. and TRABER, M.G. Vitamin E: function and metabolism. FASEB J., 13: 1145-1155, 1999.

BURTON, G.W. and TRABER, M.G. Vitamin E: antioxidant activity, biokinetics, and bioavailability. Annu. Rev. Nutr., 10: 357-382, 1990.

HOROSZEWICZ, J.S. LEONG, S.S., KAWINSKI, E., KARR, J.P., ROSENTHAL, H., CHU, T.M., MIRAND, E.A., and MURPHY, G. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.

- WARRIAR, N., PAGE, N., KOUTSILIERIS, M. and GOVINDAN, M.V. Anti-androgens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. *Prostate*, 24: 176-186, 1994.
- VELDSCHOLTE, J., BERREVOETS, C.A., and MULDER, E. Studies on the human prostatic cancer cell line LNCaP. *J. Steroid Biochem. Mol. Biol.*, 49: 341-346, 1994.
- ISRAEL, K., SANDERS, B.G., and KLINE, K. RRR- α -tocopherol succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. *Nutr. Cancer*, 24: 161-169, 1995.
- VENKATESWARAN, V., FLESHNER, N.E. and KLOTZ, L.H. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. *J. Urol.*, 168: 1578-1582, 2002.
- NI, J., CHEN, M., ZHANG, Y., LI, R., HUANG, J., and YEH, S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. *Biochem. Biophys. Res. Commun.*, 300: 357-363, 2003.
- GUNAWARDENA, K., MURRAY, D.K., and MEIKLE, A.W. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. *Prostate*, 44: 287-295, 2000.
- ISRAEL, K., YU, W., SANDERS, B.G., and KLINE, K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. *Nutr. Cancer*, 36: 90-100, 2000.
- ZHANG, Y., NI, J., MESSING, E.M., CHANG, E., YANG, C.R., and YEH, S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. *Proc. Natl. Acad. Sci. U.S.A.*, 99: 7408-7413, 2002.

WILDING, G., CHEN, M., and GELMANN, E.P. Aberrant response *in vitro* of hormone-responsive prostate cells to anti-androgens. *Prostate*, 14: 103-115, 1989.

NAKAMURA, K., YASUNAGA, Y., SEGAWA, T., KO, D., MOUL, J.W., SRIVASTAVA, S., and RHIM, J.S. Curcumin down-regulates AR gene expression and activation in prostate cancer cells. *Int. J. Oncol.*, 21: 825-830, 2002.

LE, H.T., SCHALDACH, C.M., FIRESTONE, G.L., AND BJELDANES, L.F. Plant-derived 3, 3'-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. *J. Biol. Chem.*, 278: 21136-21145, 2003.

Respectfully Submitted,

GODFREY & KAHN, S.C.

By: 

Charles L. Leeck
Registration No. 50,343

9-30-04

Attorney of Record for the Applicant
GODFREY & KAHN, S.C.
780 North Water Street
Milwaukee, WI 53202-35590
(414) 273-3500
MW848359_1.DOC



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/789,835		
		Filing Date	02/27/2004		
		First Named Inventor	THOMPSON, Todd A.		
		Art Unit	N/A		
		Examiner Name	Unknown		
Sheet	1	of	2	Attorney Docket Number	054030-0052

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRIGELIUS-FLOHE, R. et al. 1999. FASEB J. 13:1145-1155	
		BURTON, G.W. et al. 1990. Annu. Rev. Nutr., 10:357-382	
		HOROSZEWICZ, J.S. et al. 1983. Cancer Res., 43:1809-1818	
		WARRIAR, N. et al. 1994. Prostate, 24:176-186	
		VELDSCHOLTE, J. et al. 1994. J. Steroid Biochem. Mol. Biol., 49: 341-346	
		ISRAEL, K. et al. 1995. Nutr. Cancer, 24:161-169	
		VENKATESWARAN, V. et al. 2002. J. Urol., 168:1578-1582	
		NI, J. et al. 2003. Biochem. Biophys. Res. Commun., 300:357-363	
		GUNAWARDENA, K. et al. 2000. Prostate, 44:287-295	
		ISRAEL, K. et al. 2000. Nutr. Cancer, 36:90-100	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	2	Application Number	10/789,835
				Filing Date	02/27/2004
				First Named Inventor	THOMPSON, Todd A.
				Art Unit	N/A
				Examiner Name	Unknown
				Attorney Docket Number	054030-0052

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ZHANG, Y. et al. 2002. Proc. Natl. Acad. Sci. U.S.A., 99:7408-7413	
		WILDING, G. et al. 1989. Prostate, 14:103-115	
		NAKAMURA, K. et al. 2002. Int. J. Oncol., 21:825-830	
		LE, H.T. et al. 2003. J. Biol. Chem., 278:21136-21145	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.